Earnings results for Eton Pharmaceuticals (NASDAQ:ETON)
Eton Pharmaceuticals, Inc. is expected* to report earnings on 08/16/2021 after market close. The report will be for the fiscal Quarter ending Jun 2021. According to Zacks Investment Research, based on 2 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.14. The reported EPS for the same quarter last year was $-0.23.
Eton Pharmaceuticals last posted its quarterly earnings data on May 13th, 2021. The reported $0.19 EPS for the quarter, meeting analysts’ consensus estimates of $0.19. The company had revenue of $11.90 million for the quarter, compared to analyst estimates of $12.05 million. Eton Pharmaceuticals has generated ($1.33) earnings per share over the last year (($0.67) diluted earnings per share). Earnings for Eton Pharmaceuticals are expected to grow by 26.09% in the coming year, from $0.23 to $0.29 per share. Eton Pharmaceuticals has confirmed that its next quarterly earnings report will be published on Monday, August 16th, 2021. Eton Pharmaceuticals will be holding an earnings conference call on Monday, August 16th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.
Analyst Opinion on Eton Pharmaceuticals (NASDAQ:ETON)
2 Wall Street analysts have issued ratings and price targets for Eton Pharmaceuticals in the last 12 months. Their average twelve-month price target is $12.50, predicting that the stock has a possible upside of 182.81%. The high price target for ETON is $14.00 and the low price target for ETON is $11.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Eton Pharmaceuticals has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $12.50, Eton Pharmaceuticals has a forecasted upside of 182.8% from its current price of $4.42. Eton Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.
Dividend Strength: Eton Pharmaceuticals (NASDAQ:ETON)
Eton Pharmaceuticals does not currently pay a dividend. Eton Pharmaceuticals does not have a long track record of dividend growth.
Insiders buying/selling: Eton Pharmaceuticals (NASDAQ:ETON)
In the past three months, Eton Pharmaceuticals insiders have sold 13,631.48% more of their company’s stock than they have bought. Specifically, they have bought $29,800.00 in company stock and sold $4,091,980.00 in company stock. 12.92% of the stock of Eton Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health. Only 35.18% of the stock of Eton Pharmaceuticals is held by institutions.
Earnings and Valuation of Eton Pharmaceuticals (NASDAQ:ETON
Earnings for Eton Pharmaceuticals are expected to grow by 26.09% in the coming year, from $0.23 to $0.29 per share. The P/E ratio of Eton Pharmaceuticals is -6.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Eton Pharmaceuticals is -6.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Eton Pharmaceuticals has a P/B Ratio of 6.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here